Pharmacological treatment of obesity in children and adolescents: Present and future

Journal of Obesity

Volumn 2011, Issue , 2011, Pages

  Iughetti, Lorenzo ^a   China, Mariachiara ^a   Berri, Rossella ^a   Predieri, Barbara ^a  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 79959230873     PISSN: 20900708     EISSN: 20900716     Source Type: Journal    
DOI: 10.1155/2011/928165     Document Type: Review

References (100)

1. Lobstein T., Baur L., Uauy R., Obesity in children and young people: a crisis in public health. Obesity Reviews 2004 5 1 4 104 2-s2.0-3242765196 (Pubitemid 38967209)
2. Wang Y., Lobstein T., Worldwide trends in childhood overweight and obesity. International Journal of Pediatric Obesity 2006 1 1 11 25 2-s2.0-33749446753 10.1080/17477160600586747
3. Shrewsbury V., Wardle J., Socioeconomic status and adiposity in childhood: a systematic review of cross-sectional studies 1990-2005. Obesity 2008 16 2 275 284 2-s2.0-39449120535 10.1038/oby.2007.35 (Pubitemid 351271905)
4. Cooke D., Bloom S., The obesity pipeline: current strategies in the development of anti-obesity drugs. Nature Reviews Drug Discovery 2006 5 11 919 931 2-s2.0-33750510903 10.1038/nrd2136 (Pubitemid 44660605)
5. Arora S., Anubhuti, Role of neuropeptides in appetite regulation and obesity-a review. Neuropeptides 2006 40 6 375 401 2-s2.0-33751191841 10.1016/j.npep.2006.07.001 (Pubitemid 44773748)
6. Wilding J. P. H., Neuropeptides and appetite control. Diabetic Medicine 2002 19 8 619 627 2-s2.0-0036371860 10.1046/j.1464-5491.2002.00790.x (Pubitemid 34985161)
7. August G. P., Caprio S., Fennoy I., Freemark M., Kaufman F. R., Lustig R. H., Silverstein J. H., Speiser P. W., Styne D. M., Montori V. M., Prevention and treatment of pediatric obesity: an endocrine society clinical practice guideline based on expert opinion. Journal of Clinical Endocrinology and Metabolism 2008 93 12 4576 4599 2-s2.0-41849141673 10.1210/jc.2007-2458
8. Chanoine J.-P., Hampl S., Jensen C., Boldrin M., Hauptman J., Effect of orlistat on weight and body composition in obese adolescents: a randomized controlled trial. Journal of the American Medical Association 2005 293 23 2873 2883 2-s2.0-20444446770 10.1001/jama.293.23.2873 (Pubitemid 41029141)
9. Srinivasan S., Ambler G. R., Baur L. A., Garnett S. P., Tepsa M., Yap F., Ward G. M., Cowell C. T., Randomized, controlled trial of metformin for obesity and insulin resistance in children and adolescents: improvement in body composition and fasting insulin. Journal of Clinical Endocrinology and Metabolism 2006 91 6 2074 2080 2-s2.0-33744959061 10.1210/jc.2006-0241 (Pubitemid 43854985)
10. Kay J. P., Alemzadeh R., Langley G., D'Angelo L., Smith P., Holshouser S., Beneficial effects of metformin in normoglycemic morbidly obese adolescents. Metabolism 2001 50 12 1457 1461 10.1053/meta.2001.28078 (Pubitemid 34007417)
11. Freemark M., Bursey D., The effects of metformin on body mass index and glucose tolerance in obese adolescents with fasting hyperinsulinemia and a family history of type 2 diabetes. Pediatrics 2001 107 4 E55 2-s2.0-0035321014
12. Jones K. L., Arslanian S., Peterokova V. A., Park J.-S., Tomlinson M. J., Effect of metformin in pediatric patients with type 2 diabetes: a randomized controlled trial. Diabetes Care 2002 25 1 89 94 2-s2.0-0036356213 10.2337/diacare.25.1.89 (Pubitemid 41070789)
13. Berkowitz R. I., Wadden T. A., Tershakovec A. M., Cronquist J. L., Behavior therapy and sibutramine for the treatment of adolescent obesity: a randomized controlled trial. Journal of the American Medical Association 2003 289 14 1805 1812 2-s2.0-0037840394 10.1001/jama.289.14.1805 (Pubitemid 37430250)
14. Berkowitz R. I., Fujioka K., Daniels S. R., Hoppin A. G., Owen S., Perry A. C., Sothern M. S., Renz C. L., Pirner M. A., Walch J. K., Jasinsky O., Hewkin A. C., Blakesley V. A., Effects of sibutramine treatment in obese adolescents: a randomized trial. Annals of Internal Medicine 2006 145 2 81 90 2-s2.0-33746664768 (Pubitemid 46780581)
15. García-Morales L. M., Berber A., Macias-Lara C. C., Lucio-Ortiz C., Del-Rio-Navarro B. E., Dorantes-Alvárez L. M., Use of sibutramine in obese mexican adolescents: a 6-month, randomized, double-blind, placebo-controlled, parallel-group trial. Clinical Therapeutics 2006 28 5 770 782 2-s2.0-33746803704 10.1016/j.clinthera.2006.05.008 (Pubitemid 44173053)
16. Godoy-Matos A., Carraro L., Vieira A., Oliveira J., Guedes E. P., Mattos L., Rangel C., Moreira R. O., Coutinho W., Appolinario J. C., Treatment of obese adolescents with sibutramine: a randomized, double-blind, controlled study. Journal of Clinical Endocrinology and Metabolism 2005 90 3 1460 1465 2-s2.0-20144389757 10.1210/jc.2004-0263 (Pubitemid 40464005)
17. Van Mil E. G. A. H., Westerterp K. R., Kester A. D. M., Delemarre-van De Waal H. A., Gerver W. J. M., Saris W. H. M., The effect of sibutramine on energy expenditure and body composition in obese adolescents. Journal of Clinical Endocrinology and Metabolism 2007 92 4 1409 1414 2-s2.0-34147147143 10.1210/jc.2006-0264 (Pubitemid 46556418)
18. Daniels S. R., daniels.stephen@tchden.org Long B., Crow S., Styne D., Sothern M., Vargas-Rodriguez I., Harris L., Walch J., Jasinsky O., Cwik K., Hewkin A., Blakesley V., Cardiovascular effects of sibutramine in the treatment of obese adolescents: results of a randomized, double-blind, placebo-controlled study. Pediatrics 2007 120 1 e147 e157 10.1542/peds.2006-2137 (Pubitemid 47036229)
19. Hauptman J. B., Jeunet F. S., Hartmann D., Initial studies in humans with the novel gastrointestinal lipase inhibitor Ro 18-0647 (tetrahydrolipstatin). American Journal of Clinical Nutrition 1992 55 1 309S 313S 2-s2.0-0026604775
20. Padwal R. S., Majumdar S. R., Drug treatments for obesity: orlistat, sibutramine, and rimonabant. The Lancet 2007 369 9555 71 77 2-s2.0-33845874637 10.1016/S0140-6736(07)60033-6 (Pubitemid 46027230)
21. Li Z., Maglione M., Tu W., Mojica W., Arterburn D., Shugarman L. R., Hilton L., Suttorp M., Solomon V., Shekelle P. G., Morton S. C., Meta-analysis: pharmacologic treatment of obesity. Annals of Internal Medicine 2005 142 7 532 546 2-s2.0-15944367788
22. Zhi J., Moore R., Kanitra L., Mulligan T. E., Effects of orlistat, a lipase inhibitor, on the pharmacokinetics of three highly lipophilic drugs (amiodarone, fluoxetine, and simvastatin) in healthy volunteers. Journal of Clinical Pharmacology 2003 43 4 428 435 2-s2.0-0037380717 10.1177/ 0091270003252236 (Pubitemid 36368785)
23. Zhi J., Moore R., Kanitra L., Mulligan T. E., Pharmacokinetic evaluation of the possible interaction between selected concomitant medications and orlistat at steady state in healthy subjects. Journal of Clinical Pharmacology 2002 42 9 1011 1019 2-s2.0-0036708028 (Pubitemid 34920799)
24. MacWalter R. S., ronald.macwalter@tuht.scot.nhs.uk Fraser H. W., Armstrong K. M., Rivera-Miranda G., Dion P., Orlistat enhances warfarin effect. Annals of Pharmacotherapy 2003 37 4 510 512 (Pubitemid 36389658)
25. Saenz A., Fernandez-Esteban I., Mataix A., Ausejo M., Roque M., Moher D., Metformin monotherapy for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2005 3 CD002966
26. Jackson R. A., Hawa M. I., Jaspan J. B., Sim B. M., DiSilvio L., Featherbe D., Kurtz A. B., Mechanism of metformin action in non-insulin- dependent diabetes. Diabetes 1987 36 5 632 640 2-s2.0-0023551820 (Pubitemid 18024740)
27. Srinivasan S., Ambler G. R., Baur L. A., Garnett S. P., Tepsa M., Yap F., Ward G. M., Cowell C. T., Randomized, controlled trial of metformin for obesity and insulin resistance in children and adolescents: improvement in body composition and fasting insulin. Journal of Clinical Endocrinology and Metabolism 2006 91 6 2074 2080 2-s2.0-33744959061 10.1210/jc.2006-0241 (Pubitemid 43854985)
28. Stumvoll M., Nurjhan N., Perriello G., Dailey G., Gerich J. E., Metabolic effects of metformin in non-insulin-dependent diabetes mellitus. The New England Journal of Medicine 1995 333 9 550 554 2-s2.0-0029133235 10.1056/NEJM199508313330903
29. Cusi K., Consoli A., Defronzo R. A., Metabolic effects of metformin on glucose and lactate metabolism in noninsulin-dependent diabetes mellitus. Journal of Clinical Endocrinology and Metabolism 1996 81 11 4059 4067 2-s2.0-0029819936 10.1210/jc.81.11.4059 (Pubitemid 26380418)
30. Knowler W. C., Barrett-Connor E., Fowler S. E., Hamman R. F., Lachin J. M., Walker E. A., Nathan D. M., Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. The New England Journal of Medicine 2002 346 6 393 403 10.1056/NEJMoa012512 (Pubitemid 34437694)
31. Lutjens A., Smit J. L. J., Effect of biguanide treatment in obese children. Helvetica Paediatrica Acta 1976 31 6 473 480 2-s2.0-0017036470 (Pubitemid 8080013)
32. McNeely W., Goa K. L., Sibutramine. A review of its contribution to the management of obesity. Drugs 1998 56 6 1093 1124 2-s2.0-0032434821 10.2165/00003495-199856060-00019 (Pubitemid 29010230)
33. Lean M. E., How does sibutramine work? International Journal of Obesity 2001 25 4 S8 S11 2-s2.0-0034780739 (Pubitemid 34098656)
34. Barlow S. E., Expert committee recommendations regarding the prevention, assessment, and treatment of child and adolescent overweight and obesity: summary report. Pediatrics 2007 120 S164 192 2-s2.0-38449095758 10.1542/peds.2007-2329C
35. Coutinho W. F., The obese older female patient: CV risk and the SCOUT study. International Journal of Obesity 2007 31 2 S26 S30 2-s2.0-35648956293 10.1038/sj.ijo.0803733 (Pubitemid 350023171)
36. Korner J., Aronne L. J., Pharmacological approaches to weight reduction: therapeutic targets. Journal of Clinical Endocrinology and Metabolism 2004 89 6 2616 2621 2-s2.0-2942655401 10.1210/jc.2004-0341 (Pubitemid 38766340)
37. Lorber J., Obesity in childhood. A controlled trial of anorectic drugs. Archives of Disease in Childhood 1966 41 217 309 312 2-s2.0-0013918317
38. Mancini M. C., Halpern A., Pharmacological treatment of obesity. Arquivos Brasileiros de Endocrinologia e Metabologia 2006 50 2 377 389 2-s2.0-33744500755 10.1590/S0004-27302006000200024 (Pubitemid 43799121)
39. Warnock J. K., Clayton A. H., Shaw H. A., O'Donnell T., Onset of menses in two adult patients with Prader-Willi syndrome treated with fluoxetine. Psychopharmacology Bulletin 1995 31 2 239 242 2-s2.0-0028820414
40. Halford J. C. G., Harrold J. A., Boyland E. J., Lawton C. L., Blundell J. E., Serotonergic drugs: effects on appetite expression and use for the treatment of obesity. Drugs 2007 67 1 27 55 2-s2.0-33846246036 10.2165/00003495-200767010-00004 (Pubitemid 46105086)
41. Lamberts S. W. J., van der Lely A.-J., de Herder W. W., Hofland L. J., Drug therapy: octreotide. The New England Journal of Medicine 1996 334 4 255 260 2-s2.0-3643051438 (Pubitemid 126532788)
42. Krentz A. J., Boyle P. J., Macdonald L. M., Schade D. S., Octreotide: a long-acting inhibitor of endogenous hormone secretion for human metabolic investigations. Metabolism 1994 43 1 24 31 2-s2.0-0027976906 10.1016/0026-0495(94)90153-8 (Pubitemid 24047101)
43. Haqq A. M., Stadler D. D., Rosenfeld R. G., Pratt K. L., Weigle D. S., Frayo R. S., Lafranchi S. H., Cummings D. E., Purnell J. Q., Circulating ghrelin levels are suppressed by meals and octreotide therapy in children with Prader-Willi syndrome. Journal of Clinical Endocrinology and Metabolism 2003 88 8 3573 3576 2-s2.0-0042885664 10.1210/jc.2003-030205 (Pubitemid 37034497)
44. Grill H. J., Smith G. P., Cholecystokinin decreases sucrose intake in chronic decerebrate rats. American Journal of Physiology 1988 254 6 853 856 2-s2.0-0023903360
45. Lustig R. H., Greenway F., Velasquez-Mieyer P., Heimburger D., Schumacher D., Smith D., Smith W., Soler N., Warsi G., Berg W., Maloney J., Benedetto J., Zhu W., Hohneker J., A multicenter, randomized, double-blind, placebo-controlled, dose-finding trial of a long-acting formulation of octreotide in promoting weight loss in obese adults with insulin hypersecretion. International Journal of Obesity 2006 30 2 331 341 2-s2.0-32544456616 10.1038/sj.ijo.0803074 (Pubitemid 43237691)
46. Lustig R. H., Hinds P. S., Ringwald-Smith K., Christensen R. K., Kaste S. C., Schreiber R. E., Rai S. N., Lensing S. Y., Wu S., Xiong X., Octreotide therapy of pediatric hypothalamic obesity: a double-blind, placebo-controlled trial. Journal of Clinical Endocrinology and Metabolism 2003 88 6 2586 2592 2-s2.0-10744228321 (Pubitemid 36724428)
47. Velasquez-Mieyer P. A., Cowan P. A., Arheart K. L., Buffington C. K., Spencer K. A., Connelly B. E., Cowan G. W., Lustig R. H., Suppression of insulin secretion is associated with weight loss and altered macronutrient intake and preference in a subset of obese adults. International Journal of Obesity 2003 27 2 219 226 2-s2.0-0013102988 10.1038/sj.ijo.802227 (Pubitemid 36255804)
48. Ezzat S., Snyder P. J., Young W. F., Boyajy L. D., Newman C., Klibanski A., Molitch M. E., Boyd A. E., Sheeler L., Cook D. M., Malarkey W. B., Jackson I., Vance M. L., Thorner M. O., Barkan A., Frohman L. A., Melmed S., Octreotide treatment of acromegaly: a randomized, multicenter study. Annals of Internal Medicine 1992 117 9 711 718 2-s2.0-0026787125
49. Liu Y.-L., Toubro S., Astrup A., Stock M. J., Contribution of β 3-adrenoceptor activation to ephedrine induced thermogenesis in humans. International Journal of Obesity 1995 19 9 678 685 2-s2.0-0029132152
50. Astrup A., Lundsgaard C., Madsen J., Christensen N. J., Enhanced thermogenic responsiveness during chronic ephedrine treatment in man. American Journal of Clinical Nutrition 1985 42 1 83 94 2-s2.0-0021844412 (Pubitemid 15028528)
51. Greenway F., de Jonge L., Tucker E., Rood J., Smith S., Caffeine and ephedrine become more beta-3 selective with time. Obesity Research 2000 8 supplement 1 70 82
52. De Matteis R., Arch J. R. S., Petroni M. L., Ferrari D., Cinti S., Stock M. J., Immunohistochemical identification of the β 3-adrenoceptor in intact human adipocytes and ventricular myocardium: effect of obesity and treatment with ephedrine and caffeine. International Journal of Obesity 2002 26 11 1442 1450 2-s2.0-0036866711 10.1038/sj.ijo.0802148 (Pubitemid 36005774)
53. Molnár D., Török K., Erhardt E., Jeges S., Safety and efficacy of treatment with an ephedrine/caffeine mixture. The first double-blind placebo-controlled pilot study in adolescents. International Journal of Obesity 2000 24 12 1573 1578 2-s2.0-0033646869
54. Hallschmid M., Smolnik R., McGregor G., Born J., Fehm H. L., Overweight humans are resistant to the weight-reducing effects of melanocortin4-10. Journal of Clinical Endocrinology and Metabolism 2006 91 2 522 525 2-s2.0-32544440752 10.1210/jc.2005-0906 (Pubitemid 43236919)
55. Underdown N. J., Hiley C. R., Ford W. R., Anandamide reduces infarct size in rat isolated hearts subjected to ischaemia-reperfusion by a novel cannabinoid mechanism. British Journal of Pharmacology 2005 146 6 809 816 2-s2.0-27744478054 10.1038/sj.bjp.0706391 (Pubitemid 41622247)
56. Chin K.-V., Small molecule intervention for obesity. WO08048636, 2008
57. Uslu A., Pharmaceutical formulations comprising lipase inhibitor. WO2008082373, 2008
58. Ravussin E., Smith S. R., Mitchell J. A., Shringarpure R., Shan K., Maier H., Koda J. E., Weyer C., Enhanced weight loss with pramlintide/metreleptin: an integrated neurohormonal approach to obesity pharmacotherapy. Obesity 2009 17 9 1736 1743 2-s2.0-69749086148 10.1038/oby.2009.184
59. Weyer C., Tataranni P. A., Snitker S., Danforth E. Jr., Ravussin E., Increase in insulin action and fat oxidation after treatment with CL 316,243, a highly selective β 3-adrenoceptor agonist in humans. Diabetes 1998 47 10 1555 1561 2-s2.0-0031661901 10.2337/diabetes.47.10.1555 (Pubitemid 28445342)
60. Arch J. R. S., The discovery of drugs for obesity, the metabolic effects of leptin and variable receptor pharmacology: perspectives from β 3-adrenoceptor agonists. Naunyn-Schmiedeberg's Archives of Pharmacology 2008 378 2 225 240 2-s2.0-47149118684 10.1007/s00210-008-0271-1 (Pubitemid 351977641)
61. Bradley D. P., Kulstad R., Schoeller D. A., dschoell@nutrisci.wisc.edu Exenatide and weight loss. Nutrition 2010 26 3 243 249 10.1016/j.nut.2009.07.008
62. Niswender K., kevin.niswender@vanderbilt.edu Diabetes and obesity: therapeutic targeting and risk reduction-a complex interplay. Diabetes, Obesity and Metabolism 2010 12 4 267 287 10.1111/j.1463-1326.2009.01175.x
63. Ewing W. R., Mapelli C., Sulsky R. B., Human glucagon-like-peptide-1 modulators and their use in treatment of diabetes and related conditions. US20080242593, 2008
64. Hansen L., Mortensen H. B., Use of GLP1-Agonists in the treatment of patients with type I diabetes. WO2005023291, 2005
65. Korner J., Aronne L. J., Pharmacological approaches to weight reduction: therapeutic targets. Journal of Clinical Endocrinology and Metabolism 2004 89 6 2616 2621 2-s2.0-2942655401 10.1210/jc.2004-0341 (Pubitemid 38766340)
66. Li Z., Maglione M., Tu W., Mojica W., Arterburn D., Shugarman L. R., Hilton L., Suttorp M., Solomon V., Shekelle P. G., Morton S. C., Meta-analysis: pharmacologic treatment of obesity. Annals of Internal Medicine 2005 142 7 532 546 2-s2.0-15944367788
67. Bello N. T., Zahner M. R., Tesofensine, a monoamine reuptake inhibitor for the treatment of obesity. Current Opinion in Investigational Drugs 2009 10 10 1105 1116 2-s2.0-70349739420
68. Padwal R., Contrave, a bupropion and naltrexone combination therapy for the potential treatment of obesity. Current Opinion in Investigational Drugs 2009 10 10 1117 1125 2-s2.0-70349757017
69. Greenway F. L., frank.greenway@pbrc.edu Fujioka K., Plodkowski R. A., Mudaliar S., Guttadauria M., Erickson J., Kim D. D., Dunayevich E., Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet 2010 376 9741 595 605 10.1016/S0140-6736(10)60888-4
70. Bays H., Phentermine, topiramate and their combination for the treatment of adiposopathy ('sick fat') and metabolic disease. Expert Review of Cardiovascular Therapy 2010 8 12 1777 1801
71. Rinaldi-Carmona M., Barth F., Héaulme M., Alonso R., Shire D., Congy C., Soubrié P., Brelière J.-C., Le Fur G., Biochemical and pharmacological characterisation of SR141716A, the first potent and selective brain cannabinoid receptor antagonist. Life Sciences 1995 56 23-24 1941 1947 2-s2.0-0029034879 10.1016/0024-3205(95)00174-5
72. Carai M. A. M., Colombo G., Gessa G. L., Rimonabant: the first therapeutically relevant cannabinoid antagonist. Life Sciences 2005 77 19 2339 2350 2-s2.0-23944497107 10.1016/j.lfs.2005.04.017 (Pubitemid 41206861)
73. Liu Y. L., Connoley I. P., Wilson C. A., Stock M. J., Effects of the cannabinoid CB1 receptor antagonist SR141716 on oxygen consumption and soleus muscle glucose uptake in Lepob/Lep ob mice. International Journal of Obesity 2005 29 2 183 187 2-s2.0-13244249625 10.1038/sj.ijo.0802847 (Pubitemid 40188413)
74. Osei-Hyiaman D., DePetrillo M., Pacher P., Liu J., Radaeva S., Bátkai S., Harvey-White J., Mackie K., Offertáler L., Wang L., Kunos G., Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. Journal of Clinical Investigation 2005 115 5 1298 1305 2-s2.0-20944436157 10.1172/JCI200523057 (Pubitemid 40629049)
75. Cota D., Marsicano G., Tschöp M., Grübler Y., Flachskamm C., Schubert M., Auer D., Yassouridis A., Thöne-Reineke C., Ortmann S., Tomassoni F., Cervino C., Nisoli E., Linthorst A. C. E., Pasquali R., Lutz B., Stalla G. K., Pagotto U., The endogenous cennabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. Journal of Clinical Investigation 2003 112 3 423 431 2-s2.0-0041886785 10.1172/JCI200317725 (Pubitemid 38063771)
76. Després J.-P., jean-pierre.despres@crhl.ulaval.ca Golay A., Sjöström L., Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. The New England Journal of Medicine 2005 353 20 2121 2134 10.1056/NEJMoa044537 (Pubitemid 41653104)
77. Di Marzo V., Matias I., Endocannabinoid control of food intake and energy balance. Nature Neuroscience 2005 8 5 585 589 2-s2.0-17844388556 10.1038/nn1457 (Pubitemid 40594198)
78. Gómez R., Navarro M., Ferrer B., Trigo J. M., Bilbao A., Arco I. D., Cippitelli A., Nava F., Piomelli D., De Fonseca F. R., A peripheral mechanism for CB1 cannabinoid receptor-dependent modulation of feeding. Journal of Neuroscience 2002 22 21 9612 9617 2-s2.0-0036849961 (Pubitemid 35356203)
79. Gary-Bobo M., Elachouri G., Scatton B., Le Fur G., Oury-Donat F., Bensaid M., The cannabinoid CB1 receptor antagonist rimonabant (SR141716) inhibits cell proliferation and increases markers of adipocyte maturation in cultured mouse 3T3 F442A preadipocytes. Molecular Pharmacology 2006 69 2 471 478 2-s2.0-31044456243 10.1124/mol.105.015040 (Pubitemid 43121944)
80. Helvaci M. R., Kaya H., Borazan A., Ozer C., Seyhanli M., Yalcin A., Metformin and parameters of physical health. Internal Medicine 2008 47 8 697 703 2-s2.0-44649098532 10.2169/internalmedicine.47.0787 (Pubitemid 351936216)
81. Addy C., Rothenberg P., Li S., Majumdar A., Agrawal N., Li H., Zhong L., Yuan J., Maes A., Dunbar S., Cote J., Rosko K., Van Dyck K., De Lepeleire I., De Hoon J., Van Hecken A., Depré M., Knops A., Gottesdiener K., Stoch A., Wagner J., Multiple-dose pharmacokinetics, pharmacodynamics, and safety of taranabant, a novel selective cannabinoid-1 receptor inverse agonist, in healthy male volunteers. Journal of Clinical Pharmacology 2008 48 6 734 744 2-s2.0-44049088873 10.1177/0091270008317591 (Pubitemid 351713158)
82. Adler R., Landa K. B., Manthorpe M., Varon S., Cholinergic neuronotrophic factors: intraocular distribution of trophic activity for ciliary neurons. Science 1979 204 4400 1434 1436 2-s2.0-0018764763 (Pubitemid 9212230)
83. Lin L.-F. H., Mismer D., Lile J. D., Armes L. G., Butler E. T. III, Vannice J. L., Collin F., Purification, cloning, and expression of ciliary neurotrophic factor (CNTF). Science 1989 246 4933 1023 1025 2-s2.0-0024409029 (Pubitemid 20010526)
84. Davis S., Aldrich T. H., Valenzuela D. M., Wong V., Furth M. E., Squinto S. P., Yancopoulos G. D., The receptor for ciliary neurotrophic factor. Science 1991 253 5015 59 63 2-s2.0-0025783668 (Pubitemid 21917117)
85. Ip N. Y., Nye S. H., Boulton T. G., Davis S., Taga T., Li Y., Birren S. J., Yasukawa K., Kishimoto T., Anderson D. J., Stahl N., Yancopoulos G. D., CNTF and LIF act on neuronal cells via shared signaling pathways that involve the IL-6 signal transducing receptor component gp130. Cell 1992 69 7 1121 1132 2-s2.0-0026634735 10.1016/0092-8674(92)90634-O
86. Sendtner M., Arakawa Y., Stockli K. A., Kreutzberg G. W., Thoenen H., Effect of ciliary neurotrophic factor (CNTF) on motoneuron survival. Journal of Cell Science 1991 100 15 103 109 2-s2.0-0026286156
87. Miller R. G., Petajan J. H., Bryan W. W., Armon C., Barohn R. J., Goodpasture J. C., Hoagland R. J., Parry G. J., Ross M. A., Stromatt S. C., A placebo-controlled trial of recombinant human ciliary neurotrophic (rhCNTF) factor in amyotrophic lateral sclerosis. Annals of Neurology 1996 39 2 256 260 2-s2.0-9044219848 10.1002/ana.410390215 (Pubitemid 26071576)
88. Pan W., Kastin A. J., Maness L. M., Brennan J. M., Saturable entry of ciliary neurotrophic factor into brain. Neuroscience Letters 1999 263 1 69 71 2-s2.0-0033582965 10.1016/S0304-3940(99)00083-X (Pubitemid 29138965)
89. Xu B., Dube M. G., Kalra P. S., Farmerie W. G., Kaibara A., Moldawer L. L., Martin D., Kalra S. P., Anorectic effects of the cytokine, ciliary neurotropic factor, are mediated by hypothalamic neuropeptide Y: comparison with leptin. Endocrinology 1998 139 2 466 473 2-s2.0-0031788012 10.1210/en.139.2.466 (Pubitemid 28513190)
90. Lambert P. D., Anderson K. D., Sleeman M. W., Wong V., Tan J., Hijarunguru A., Corcoran T. L., Murray J. D., Thabet K. E., Yancopoulos G. D., Wiegand S. J., Ciliary neurotrophic factor activates leptin-like pathways and reduces body fat, without cachexia or rebound weight gain, even in leptin-resistant obesity. Proceedings of the National Academy of Sciences of the United States of America 2001 98 8 4652 4657 2-s2.0-0035836760 10.1073/pnas.061034298 (Pubitemid 32295031)
91. Zvonic S., Cornelius P., Stewart W. C., Mynatt R. L., Stephens J. M., The regulation and activation of ciliary neurotrophic factor signaling proteins in adipocytes. Journal of Biological Chemistry 2003 278 4 2228 2235 2-s2.0-0037462739 10.1074/jbc.M205871200 (Pubitemid 36801290)
92. Scott M., Methods for identifyng a candidate for treatment of obesity. WO2006017156, 2006
93. Bengtsson B.-A., Eden S., Lonn L., Kvist H., Stokland A., Lindstedt G., Bosaeus I., Tolli J., Sjostrom L., Isaksson O. G. P., Treatment of adults with growth hormone (GH) deficiency with recombinant human GH. Journal of Clinical Endocrinology and Metabolism 1993 76 2 309 317 2-s2.0-0027514167 10.1210/jc.76.2.309 (Pubitemid 23073047)
94. Ng F. M., Sun J., Sharma L., Libinaka R., Jiang W. J., Gianello R., Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone. Hormone Research 2000 53 6 274 278 2-s2.0-0034521466 10.1159/000053183 (Pubitemid 32037592)
95. Wikberg J. E., Mutulis F., Targeting melanocortin receptors: an approach to treat weight disorders and sexual dysfunction. Nature reviews. Drug discovery 2008 7 4 307 323 2-s2.0-42149124403 10.1038/nrd2331
96. Diamond L. E., Earle D. C., Rosen R. C., Willett M. S., Molinoff P. B., Double-blind, placebo-controlled evaluation of the safety, pharmacokinetic properties and pharmacodynamic effects of intranasal PT-141, a melanocortin receptor agonist, in healthy males and patients with mild-to-moderate erectile dysfunction. International Journal of Impotence Research 2004 16 1 51 59 2-s2.0-1642483808 10.1038/sj.ijir.3901139 (Pubitemid 38401559)
97. Beck J. P., Wakefield B. D., Novel mch receptor antagonists. CN101072775, 2007
98. Houghten R. A., Dooley C., Nefzi A., Wang Z., Civelli O., Nagasaki H., Melanin-concentrating hormone receptor antagonists and methods of use. US 20080255218, 2008
99. Luthin D. R., Anti-obesity effects of small molecule melanin- concentrating hormone receptor1 (MCHR1) antagonists. Life Sciences 2007 81 6 423 440 2-s2.0-34547476684 10.1016/j.lfs.2007.05.029 (Pubitemid 47175968)
100. Anderson K. A., Ribar T. J., Lin F., Noeldner P. K., Green M. F., Muehlbauer M. J., Witters L. A., Kemp B. E., Means A. R., Hypothalamic CaMKK2 contributes to the regulation of energy balance. Cell Metabolism 2008 7 5 377 388 2-s2.0-42649105456 10.1016/j.cmet.2008.02.011 (Pubitemid 351598022)